ASTH — Stock Film
STOCK FILMSCENE 1/11ASTH · $39.35
Stock Expert AI presents
ASTH
Astrana Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Astrana Health, Inc. A quick introduction.

On the stock market since 2009, it operates in the world of health and science. It has 1,900 employees. Now — the numbers.

on the stock market since 2009
1,900 employees
$1.9B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $1 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 1%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
92%Health Care Capitation Revenue
Health Care Capitation Revenue 92%Health Care, Patient Service 4%Health Care, Other 3%Management Service 1%Product and Service, Other 1%
92% of all revenue comes from a single line: Health Care Capitation Revenue.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 42% a year over the last 4 years. Every year shown ended in profit.

$773.9M
2021
$1.1B
2022
$1.4B
2023
$2B
2024
$3.2B
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
70
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
21
very weak

Clearly below the class average.

VALUATION
89
very strong

The price looks reasonable next to what the company earns.

GROWTH
95
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
74
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Thin profit on each sale3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 41% a year on average.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $51.8032% above today’s price.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 83 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 21/100.

3
THE RISKS · 3/3
Thin profit on each sale

As the slice kept from each sale thins out, so does the profit. Council score: 3/10.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, ASTH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ASTH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film